Ophtec Secures CE Marking for Aspheric Presbyopia-Correcting IOL

May 12, 2017: By Jon Swedien

OphtecOphtec has received CE marking for its Precizon Presbyopic, a new aspheric presbyopia-correcting IOL, the Netherlands company announced May 6.

The lens will be commercially launched in October 2017 during the annual conference of the European Society of Cataract and Refractive Surgeons in Lisbon, Portugal.

The product will initially be available in the European Union and a few selected markets, Ophtec said.

The Precizon Presbyopic IOL features a patent-pending continuous transitional focus (CTF) optical design.

The CTF design’s transitional zones offer a smooth, continuous transition from near to infinity vision, enabling surgeons to treat a wider range of presbyopic patients with confidence, Ophtec said.

The IOL appears to be able to forgive larger degrees of lens tilt and decentration, and this tolerance reduces photic phenomena, helping patients to adapt more naturally to their new vision, Ophtec said.

The lens is also designed to be less dependent on pupil size under all lighting conditions, Ophtec said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US FDA Grants De Novo Request for IDx-DR’s AI Diagnostic System for Diabetic Retinopathy

Allergan Launches TrueTear Intranasal Neurostimulation Device for Dry Eye

Novartis Acquires AveXis, Gene Therapy Platform for $8.7 Billion

Samsung, Biogen Reach Deal with AbbVie over Humira Biosimilar

EyePoint Secures Two US Patents for DEXYCU

SightLife Surgical Rebrands as CorneaGen, Offers New Products

Omidria Earns Listing on VA Formulary, Regains CMS Pass-Through Status

Rayner Launching 600C Monofocal Aspheric IOL in US

LENSAR Laser System Receives 510(k) Clearance for Corneal Pockets, Flaps

EyeGate Completes Enrollment, Receives Milestone Payment for Phase III Study of EGP-437 in Anterior Uveitis

SAV-IOL Seeks $20M in Financing for Active Intraocular Lens Concept with Real-Time Autofocus

AGTC Completes Enrollment for Phase I/II Study of Gene Therapy for X-linked Retinoschisis

Robert Greenberg, MD, PhD, Resigns from Second Sight

US FDA Requires RegeneRx to Conduct Third Phase III Trial for Dry Eye Candidate RGN-259

Stem Cell Implant Yields Positive Results in Phase I/II Study in Dry AMD

Drug Companies Petition Supreme Court to Hear Case Challenging Eye Drop Size

Appeals Court Rules in Favor of Alcon in Suit Brought by Elenza over EAIOLs

ThromboGenics’ THR-137 Demonstrates Safety, Tolerability in Phase I/II Study in DME

GenSight Biologics’ LHON Candidate Improves Eyesight, Fails to Outpace Sham in Phase III Trial

I-MED Pharma’s I-PEN Receives Regulatory Approval in Colombia, Argentina

Coming soon

2018 China Ophthalmic Market Report: An Analysis for 2017 to 2023